Other
97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
Paper Details
Title
97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
Published Date
Mar 27, 2021
Journal
Volume
16
Issue
4
Pages
S748 - S749
Notes
History